For research use only. Not for therapeutic Use.
Naftopidil dihydrochloride (Cat No.:A000616) is a selective α1-adrenoceptor antagonist used primarily in the treatment of benign prostatic hyperplasia (BPH). By blocking α1-adrenoceptors in the smooth muscle of the prostate and bladder, Naftopidil helps alleviate symptoms such as urinary frequency, urgency, and nocturia. It works by relaxing the muscles around the prostate and improving urinary flow. Additionally, Naftopidil has some selectivity for the α1A subtype of adrenoceptors, which contributes to its effectiveness in reducing BPH symptoms while minimizing cardiovascular side effects. It is commonly prescribed in Japan and other regions for BPH management.
| Catalog Number | A000616 |
| CAS Number | 57149-08-3 |
| Synonyms | KT-611 |
| Molecular Formula | C24H30Cl2N2O3 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO > 10 mM |
| Storage | 3 years -20C powder |
| IUPAC Name | 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol;dihydrochloride |
| InChI | InChI=1S/C24H28N2O3.2ClH/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23;;/h2-12,20,27H,13-18H2,1H3;2*1H |
| InChIKey | HZVCEQMJXMUXJF-UHFFFAOYSA-N |
| SMILES | COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC=CC4=CC=CC=C43)O.Cl.Cl |
